Q-omics provides the consensus-scored HSFX1 profile across patient tissues and cancer cell-line models. HSFX1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, HSFX1 is differentially expressed in 6, with the highest sampling consensus in ESCA. Additionally, HSFX1 RNA expression shows 10,531 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ESCA, and THYM as cancer lineages where HSFX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSFX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSFX1 survival associations across molecular data types. HSFX1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSFX1 RNA expression–survival associations across cancer types. High HSFX1 expression shows unfavorable associations in ESCA, STAD and ACC, but favorable associations in LUAD, UVM and SARC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify ESCA as the clearest survival context for HSFX1 RNA expression.
This table summarizes HSFX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for HSFX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSFX1 shows lower tumor expression in ESCA, PRAD and COAD and higher tumor expression in HNSC, LIHC and CHOL. The ESCA box plot shows higher HSFX1 RNA expression in normal versus tumor tissue (log2 FC = −0.094, t-test p = .044).
This table shows molecular features associated with HSFX1 in patient tissues and cancer cell lines. In patient samples, HSFX1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, HSFX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
